Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights Into Cardiovascular Disease in Women From the Framingham Heart Study.

JACC. Advances·2026
Same author

2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.

Circulation·2026
Same author

Sustained mesenchymal reprogramming of endothelial cells after completion of chemotherapy.

Cardio-oncology (London, England)·2025
Same author

Exploring Diabetes Clinical Trial Participation: A Diverse Group Interview Study.

Therapeutic innovation & regulatory science·2025
Same author

PKM2 is a key regulator of cardiac lipid metabolism in mice.

Mitochondrion·2025
Same author

Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.

Circulation·2025
Same journal

In-Hospital Cardiac Arrest Detection Performance Analysis and Comparison on Effective Feature Selection.

Clinical cardiology·2026
Same journal

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy.

Clinical cardiology·2026
Same journal

Heart Failure With Preserved Ejection Fraction-Like Phenotype in Coronary Artery Disease and Obstructive Sleep Apnea: Insights From the RICCADSA Cohort.

Clinical cardiology·2026
Same journal

Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.

Clinical cardiology·2026
Same journal

Methodological Considerations Regarding Diuretic Intensity Score and Mortality in Hospitalized Heart Failure Patients.

Clinical cardiology·2026
Same journal

Inpatient Outcomes and Complications After Left Atrial Appendage Occlusion in Rural Versus Urban Hospitals in the United States.

Clinical cardiology·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Methamphetamine-associated cardiomyopathy.

Sekon Won1, Robert A Hong, Ralph V Shohet

  • 1John A. Burns School of Medicine University of Hawaii at Manoa Honolulu, Hawaii.

Clinical Cardiology
|September 17, 2013
PubMed
Summary
This summary is machine-generated.

Methamphetamine-associated cardiomyopathy (MAC) is an increasing concern. This review details methamphetamine

More Related Videos

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

Related Experiment Videos

Last Updated: May 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

Area of Science:

  • Cardiology
  • Toxicology
  • Pharmacology

Background:

  • Methamphetamine is the second most used illicit drug globally.
  • Methamphetamine-associated cardiomyopathy (MAC) reports are rising.
  • Existing literature on MAC is limited.

Purpose of the Study:

  • To provide a comprehensive review of methamphetamine-associated cardiomyopathy (MAC).
  • To discuss the pharmacology, epidemiology, and proposed mechanisms of MAC.
  • To identify clinical questions and research gaps concerning MAC.

Main Methods:

  • Review of existing case and clinical studies on MAC.
  • Analysis of methamphetamine pharmacology and epidemiology.
  • Synthesis of proposed pathophysiological mechanisms for MAC.

Main Results:

  • Methamphetamine use is linked to increasing cardiac pathology.
  • Proposed mechanisms for MAC involve direct toxicity and other factors.
  • Significant clinical questions regarding MAC diagnosis and treatment persist.

Conclusions:

  • Physician awareness of MAC is crucial due to rising stimulant use.
  • Further research is needed on MAC incidence, risk factors, and prognosis.
  • Optimal therapeutic interventions for MAC require further investigation.